RARE — Ultragenyx Pharmaceutical Cashflow Statement
0.000.00%
Last trade - 00:00- $3.69bn
- $3.09bn
- $560.23m
Annual cashflow statement for Ultragenyx Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -187 | -454 | -707 | -607 | -569 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -62.6 | 165 | 249 | 121 | 106 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 105 | -63.2 | 61.9 | -13.5 | 13.9 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -132 | -339 | -380 | -475 | -414 |
| Capital Expenditures | -43.9 | -73.1 | -146 | -46.8 | -20 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -135 | -122 | -146 | 215 | 2.22 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -179 | -195 | -292 | 168 | -17.8 |
| Financing Cash Flow Items | -0.236 | -0.492 | 490 | -0.028 | 7 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 600 | 119 | 501 | 388 | 399 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 290 | -417 | -172 | 81.8 | -35.2 |